Literature DB >> 21668435

Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics.

S Donnou1, C Galand, C Daussy, L Crozet, W H Fridman, C Sautès-Fridman, S Fisson.   

Abstract

A large body of evidence indicates that the immune microenvironment controls tumour development. Primary central nervous system lymphomas (PCNSL) are aggressive tumours growing in the central nervous system (CNS). To evaluate the role and characteristics of this immune-privileged site in anti-tumour defences, we compared the cellular and molecular immune microenvironments of growing murine lymphoma B cells injected into the brain or the spleen. In the brain, immune cells, including dendritic cells and T lymphocytes with a large proportion of CD4(+) forkhead box P3 (FoxP3(+)) regulatory T cells, rapidly infiltrated the tumour microenvironment. These populations also increased in number in the spleen. The T cell cytokine profiles in tumour-bearing mice were similar in the two sites, with predominant T helper type 1 (Th1)/Th17 polarization after polyclonal stimulation, although some interleukin (IL)-4 could also be found. We demonstrated that these T cells have anti-tumour activity in the CNS, although less than in the spleen: nude mice that received lymphoma cells intracerebrally died significantly earlier than immunocompetent animals. These results demonstrate that the brain is able to recruit all the major actors to mount a specific anti-tumour immune response against lymphoma.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668435      PMCID: PMC3170982          DOI: 10.1111/j.1365-2249.2011.04416.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.

Authors:  Axel Nimmerjahn; Frank Kirchhoff; Fritjof Helmchen
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

2.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases.

Authors:  Sophie Camilleri-Broët; Emmanuelle Crinière; Philippe Broët; Vincent Delwail; Karima Mokhtari; Anne Moreau; Michèle Kujas; Martine Raphaël; Wafae Iraqi; Catherine Sautès-Fridman; Philippe Colombat; Khê Hoang-Xuan; Antoine Martin
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Impaired capacity for upregulation of MHC class II in tumor-associated microglia.

Authors:  Jill M Schartner; Aaron R Hagar; Michelle Van Handel; Leying Zhang; Nivedita Nadkarni; Behnam Badie
Journal:  Glia       Date:  2005-09       Impact factor: 7.452

4.  Rat choroid plexuses contain myeloid progenitors capable of differentiation toward macrophage or dendritic cell phenotypes.

Authors:  Serge Nataf; Nathalie Strazielle; Eric Hatterer; Guy Mouchiroud; Marie-Françoise Belin; Jean-François Ghersi-Egea
Journal:  Glia       Date:  2006-08-15       Impact factor: 7.452

Review 5.  Current management of primary central nervous system lymphoma.

Authors:  Christopher J Schultz; Joseph Bovi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

6.  Site-specific immune response to implanted gliomas.

Authors:  M A Proescholdt; M J Merrill; B Ikejiri; S Walbridge; A Akbasak; S Jacobson; E H Oldfield
Journal:  J Neurosurg       Date:  2001-12       Impact factor: 5.115

7.  Brain dendritic cells and macrophages/microglia in central nervous system inflammation.

Authors:  H G Fischer; G Reichmann
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

8.  Differential expression of MHC class II and B7 costimulatory molecules by microglia in rodent gliomas.

Authors:  Behnam Badie; Becky Bartley; Jill Schartner
Journal:  J Neuroimmunol       Date:  2002-12       Impact factor: 3.478

9.  Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.

Authors:  Ching-Hung Lin; Kuan-Ting Kuo; Shih-Sung Chuang; Sung-Hsin Kuo; Julia Hueimei Chang; Kung-Chao Chang; Hui-Chen Hsu; Hwei-Fang Tien; Ann-Lii Cheng
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

10.  What is immune privilege (not)?

Authors:  Ian Galea; Ingo Bechmann; V Hugh Perry
Journal:  Trends Immunol       Date:  2006-11-28       Impact factor: 16.687

View more
  5 in total

Review 1.  Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Authors:  Rym Ben Abdelwahed Bagga; Sabrina Donnou; Jérémie Cosette; Catherine Sautès-Fridman; Mahjoub Aouni; Sylvain Fisson
Journal:  J Neurooncol       Date:  2014-10-10       Impact factor: 4.130

2.  Murine models of B-cell lymphomas: promising tools for designing cancer therapies.

Authors:  Sabrina Donnou; Claire Galand; Valérie Touitou; Catherine Sautès-Fridman; Zsuzsanna Fabry; Sylvain Fisson
Journal:  Adv Hematol       Date:  2012-02-12

3.  Effective antituberculous therapy in a patient with CLIPPERS: New insights into CLIPPERS pathogenesis.

Authors:  Nicolas Mélé; Vincent Guiraud; Pierre Labauge; Catherine Oppenheim; Jean Louis Mas; Guillaume Taieb
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-04-24

4.  Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

Authors:  Claire Galand; Sabrina Donnou; Thierry Jo Molina; Wolf Herman Fridman; Sylvain Fisson; Catherine Sautès-Fridman
Journal:  Front Immunol       Date:  2012-05-04       Impact factor: 7.561

Review 5.  Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.

Authors:  Manuel Montesinos-Rongen; Anna Brunn; Monica Sanchez-Ruiz; Ralf Küppers; Reiner Siebert; Martina Deckert
Journal:  Cancers (Basel)       Date:  2021-12-17       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.